Loading...
Loading...
INDP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.7K |
| Gross Profit | -0.7K |
| Operating Expense | 3,942.5K |
| Operating I/L | -3,943.2K |
| Other Income/Expense | 136.6K |
| Interest Income | 0.0K |
| Pretax | -3,806.7K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,806.7K |
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company specializing in the development of anti-cancer and anti-viral immunotherapy products. Their lead clinical oncology candidate, Decoy20, is designed for single agent activity and combination therapy-based durable responses in lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection. The company is currently in the Phase I clinical trial stage for this product. Indaptus Therapeutics, Inc. focuses on developing innovative treatments for cancer and viral infections, aiming to generate revenue through the successful commercialization of their immunotherapy products.
